Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors

Sampa Santra, Yue Sun, Birgit Korioth-Schmitz, Julie Fitzgerald, Cherie Charbonneau, Giannina Santos, Michael S. Seaman, Sarah J. Ratcliffe, David C. Montefiori, Gary J. Nabel, Hildegund C J Ertl, Norman L. Letvin

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both preclinical studies and clinical trials. As a potential solution to this problem we developed adenovirus vaccine vectors of chimpanzee origin. In the present study we assessed the immunogenicity of various chimpanzee adenovirus vectors in a prime/boost regimen to HIV-1 envelope and SIV Gag-Pol in rhesus monkeys and their ability to protect against pathogenic viral challenge. Although rAdHu5-primed monkeys had higher magnitude T cell responses than rAdC7 or rAdC68 prior to challenge, the rAdC7-rAdC1/C5 and rAdHu5-rAdC1/C5 immunizations resulted in comparable magnitude recall cellular immune responses and comparable level of control of viremia post-challenge.

Original languageEnglish (US)
Pages (from-to)5837-5845
Number of pages9
Issue number42
StatePublished - Sep 25 2009
Externally publishedYes


  • Chimpanzee adenovirus
  • HIV-1 vaccine

ASJC Scopus subject areas

  • General Immunology and Microbiology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • General Veterinary
  • Molecular Medicine


Dive into the research topics of 'Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors'. Together they form a unique fingerprint.

Cite this